The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kazuomi Ueshima
Honoraria - Bayer; Eisai; Lilly Japan
Consulting or Advisory Role - Chugai Pharma; Eisai; Lilly Japan; Pfizer
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Shire; Takeda; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Takuji Torimura
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Takeda (Inst)
 
Hiroshi Aikata
Consulting or Advisory Role - Bayer; Eisai
 
Namiki Izumi
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bayer; Eisai
 
Takahiro Yamasaki
No Relationships to Disclose
 
Keisuke Hino
No Relationships to Disclose
 
Teiji Kuzuya
Honoraria - Bayer
 
Norio Isoda
Research Funding - Abbvie; EA Pharma; Eisai
 
Kohichiroh Yasui
No Relationships to Disclose
 
Hajime Aino
No Relationships to Disclose
 
Akio Ido
No Relationships to Disclose
 
Naoto Kawabe
No Relationships to Disclose
 
Kazuhiko Nakao
Honoraria - Gilead Sciences
 
Yoshiyuki Wada
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
 
Takuji Okusaka
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly; Meiji Seika Kaisha; MSD; Mundipharma; Nippon Shinyaku; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Takara Bio
 
Junji Furuse
Honoraria - Abbvie; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Shionogi; Shire; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Lilly Japan; Merck; MSD; Mundipharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yasuaki Arai
Speakers' Bureau - Listed on bellow additional info
Patents, Royalties, Other Intellectual Property - Sumitomo Chemical